Skip to main content
. Author manuscript; available in PMC: 2012 Jun 11.
Published in final edited form as: J Biol Inorg Chem. 2010 Mar 11;15(5):737–748. doi: 10.1007/s00775-010-0642-1

Fig. 7.

Fig. 7

a Drug–protein binding pattern of KP1019 determined by SEC-SEC-ICP-MS (designed for the separation of large proteins). Cytosolic fractions of KP1019-treated KB-3-1 cells were prepared after 3-h drug treatment. b Drug-protein binding pattern of KP1019 determined by SEC-ICP-MS after implementation of an alternative cell compartment fractionation protocol. Cytosolic 100,000g supernatant fractions not containing organelles, particular protein complexes, as well as membrane-bound proteins (fraction III) of KP1019-treated KB-3-1 cells were prepared after 3-h drug treatment